L-Thyroxine sodium

Modify Date: 2024-01-02 17:36:37

L-Thyroxine sodium Structure
L-Thyroxine sodium structure
Common Name L-Thyroxine sodium
CAS Number 55-03-8 Molecular Weight 798.852
Density N/A Boiling Point 576.3ºC at 760 mmHg
Molecular Formula C15H20I4NNaO9 Melting Point 207-210 (dec.)(lit.)ºC
MSDS N/A Flash Point 302.3ºC

 Use of L-Thyroxine sodium


L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4)[1].

 Names

Name levothyroxine sodium anhydrous
Synonym More Synonyms

 L-Thyroxine sodium Biological Activity

Description L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4)[1].
Related Catalog
In Vivo Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion[1]. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03)[2].
References

[1]. Arici M, et al. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323.

[2]. Corriveau S, et al. Levothyroxine treatment generates an abnormal uterine contractility patterns in an in vitro animalmodel. J Clin Transl Endocrinol. 2015 Sep 9;2(4):144-149.

 Chemical & Physical Properties

Boiling Point 576.3ºC at 760 mmHg
Melting Point 207-210 (dec.)(lit.)ºC
Molecular Formula C15H20I4NNaO9
Molecular Weight 798.852
Flash Point 302.3ºC
Exact Mass 798.668579
PSA 141.76000
LogP 3.60140

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XP3583000
CHEMICAL NAME :
Thyroxine, monosodium salt, L-
CAS REGISTRY NUMBER :
55-03-8
LAST UPDATED :
199710
DATA ITEMS CITED :
15
MOLECULAR FORMULA :
C15-H11-I4-N-O4.Na
MOLECULAR WEIGHT :
799.86
WISWESSER LINE NOTATION :
QR BI FI DOR BI FI D1YZVO &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
14 mg/kg/14D-I
TOXIC EFFECTS :
Behavioral - coma Cardiac - change in rate Gastrointestinal - hypermotility, diarrhea
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 3,297,1985
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
900 ug/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Endocrine - evidence of thyroid hypofunction
REFERENCE :
AJEMEN American Journal of Emergency Medicine. (WB Saunders, Philadelphia, PA) V.1- 1983- Volume(issue)/page/year: 3,297,1985
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
449 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate increase, without fall in BP Vascular - BP elevation not characterized in autonomic section
REFERENCE :
AEMED3 Annals of Emergency Medicine. (American College of Emergency Physicians, 1125 Executive Circle, Irving, TX 75038) Volume(issue)/page/year: 14,1114,1985
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
117 ug/kg/60D-I
TOXIC EFFECTS :
Behavioral - headache
REFERENCE :
AJDCAI American Journal of Diseases of Children. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-80(3), 1911-50; V.100- 1960- Volume(issue)/page/year: 138,927,1984
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
20 ug/kg
TOXIC EFFECTS :
Behavioral - excitement Cardiac - pulse rate increase, without fall in BP Nutritional and Gross Metabolic - body temperature increase
REFERENCE :
AJDCAI American Journal of Diseases of Children. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-80(3), 1911-50; V.100- 1960- Volume(issue)/page/year: 141,1025,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
20 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,905,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
50 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,905,1982 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
6750 ug/kg
SEX/DURATION :
female 10 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - other postnatal measures or effects
REFERENCE :
BNEOBV Biology of the Neonate. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.15- 1970- Volume(issue)/page/year: 31,71,1977
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2 mg/kg
SEX/DURATION :
female 9-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
DPTHDL Developmental Pharmacology and Therapeutics. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1980- Volume(issue)/page/year: 2,17,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
8 mg/kg
SEX/DURATION :
female 9-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
JDREAF Journal of Dental Research. (International Assoc. for Dental Research, 734 15th St., NW, Suite 809, Washington, DC 20005) V.1- 1919- Volume(issue)/page/year: 53(Spec Iss),541,1974
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
30 ug/kg
SEX/DURATION :
female 28-30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - stillbirth
REFERENCE :
BNEOBV Biology of the Neonate. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.15- 1970- Volume(issue)/page/year: 22,161,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80525 No. of Facilities: 68 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 2770 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80525 No. of Facilities: 131 (estimated) No. of Industries: 1 No. of Occupations: 4 No. of Employees: 2447 (estimated) No. of Female Employees: 1413 (estimated)

 Safety Information

Safety Phrases S22-S24/25
RIDADR UN 2811
WGK Germany 3
RTECS YP2833760
Packaging Group II
Hazard Class 6.1(a)

 Synthetic Route

~99%

L-Thyroxine sodium Structure

L-Thyroxine sodium

CAS#:55-03-8

Literature: CADILA PHARMACEUTICALS LTD. Patent: WO2009/136249 A1, 2009 ; Location in patent: Page/Page column 5 ;

 Precursor & DownStream

Precursor  1

DownStream  0

 Synonyms

Sodium l-thyroxin
L-3,3',5,5'-Tetraiodothyronine Sodium Salt
L-Thyroxine monosodium salt
Levaxin
Euthyrox
L-Tyrosine, O- (4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt
Sodium Levothyroxine
Eltroxin
Thyro-Tabs
O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine Monosodium Salt
Levothroid
L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1)
EINECS 200-221-4
SODIUM L-THYROXINE
Synthroid
L-Thyroxine sodium salt
Sodium (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate
Levothyroxine sodium
Oroxine
(S)-2-Amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propionic Acid Sodium Salt Pentahydrate
Levoxyl
Top Suppliers:I want be here




Get all suppliers and price by the below link:

L-Thyroxine sodium suppliers


Price: ¥148.2/1g

Reference only. check more L-Thyroxine sodium price